1. Search Result
Search Result
Results for "

monoamine neurotransmitters

" in MedChemExpress (MCE) Product Catalog:

40

Inhibitors & Agonists

1

Bibliotecas de Screening

8

Natural
Products

7

Isotope-Labeled Compounds

Cat. No. Nombre del producto Target Áreas de investigación Chemical Structure
  • HY-B1473A
    Serotonin
    Maximum Cited Publications
    31 Publications Verification

    5-Hydroxytryptamine; 5-HT

    5-HT Receptor COMT Endogenous Metabolite Neurological Disease
    Serotonin is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM.
    Serotonin
  • HY-B1473
    Serotonin hydrochloride
    Maximum Cited Publications
    31 Publications Verification

    5-Hydroxytryptamine hydrochloride; 5-HT hydrochloride

    5-HT Receptor COMT Endogenous Metabolite Neurological Disease
    Serotonin (5-Hydroxytryptamine) hydrochloride is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist, with blood-brain barrier permeability. Serotonin hydrochloride is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM.
    Serotonin hydrochloride
  • HY-B1473AS

    5-Hydroxytryptamine-d4; 5-HT-d4

    Isotope-Labeled Compounds 5-HT Receptor COMT Endogenous Metabolite Neurological Disease
    Serotonin-d4 is deuterium labeled Serotonin. Serotonin is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM.
    Serotonin-d4
  • HY-14472

    NS-2330

    Dopamine Transporter Serotonin Transporter Metabolic Disease
    Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .
    Tesofensine
  • HY-B0528A
    Octopamine hydrochloride
    5 Publications Verification

    (±)-p-Octopamine hydrochloride

    Adrenergic Receptor Endogenous Metabolite Neurological Disease Endocrinology
    Octopamine ((±)-p-Octopamine) hydrochloride, a biogenic monoamine structurally related to noradrenaline, acts as a neurohormone, a neuromodulator and a neurotransmitter in invertebrates. Octopamine hydrochloride can stimulate alpha2-adrenoceptors (ARs) in Chinese hamster ovary cells transfected with human alpha2-ARs. Octopamine hydrochloride increased glycogenolysis, glycolysis, oxygen uptake, gluconeogenesis and the portal perfusion pressure .
    Octopamine hydrochloride
  • HY-B1018A
    Phenelzine sulfate
    5+ Cited Publications

    Monoamine Oxidase GABA Receptor Histone Demethylase Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer .
    Phenelzine sulfate
  • HY-B0886A
    Iproniazid
    2 Publications Verification

    Monoamine Oxidase Apoptosis Neurological Disease Metabolic Disease Endocrinology
    Iproniazid is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid can be used in the research of depression, Parkinson's disease, and hepatotoxicity .
    Iproniazid
  • HY-N2554

    Ostenol

    Monoamine Oxidase PI3K Akt Apoptosis Infection Neurological Disease Cancer
    Osthenol (Ostenol) is a reversible, selective, competitive inhibitor of hMAO-A (IC50=0.74 μM, Ki=0.26 μM), with antifungal and antibacterial activity. Osthenol inhibits the oxidative deamination of hMAO-A and regulates the metabolism of monoamine neurotransmitters. Osthenol also inhibits the PI3K/AKT signaling pathway to induce apoptosis of colon cancer cells, arrest the cell cycle at the G1 phase, and inhibit cell proliferation. Osthenol is mainly used in the study of neurological diseases and cancer, especially depression-related MAO-A targeted intervention and colon cancer .
    Osthenol
  • HY-B1473S

    5-Hydroxytryptamine-d4 hydrochloride; 5-HT-d4 hydrochloride

    Isotope-Labeled Compounds 5-HT Receptor Endogenous Metabolite COMT Others
    Serotonin-d4 (5-Hydroxytryptamine-d4) hydrochloride is the deuterium labeled Serotonin (hydrochloride) (HY-B1473) . Serotonin (5-Hydroxytryptamine) hydrochloride is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin hydrochloride is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM .
    Serotonin-d4 hydrochloride
  • HY-14197
    Clorgyline
    5+ Cited Publications

    M&B 9302

    Monoamine Oxidase Neurological Disease
    Clorgyline (M&B 9302) is an orally active, blood-brain barrier permeable and selective monoamine oxidase A (MAO-A) inhibitor. Clorgyline's selective inhibition of MAO-A leads to reduced metabolism of neurotransmitters such as serotonin (5-hydroxytryptamine), which accumulates in the brain. Clorgyline can be used in the study of depression and neurodegenerative diseases .
    Clorgyline
  • HY-B0886
    Iproniazid phosphate
    2 Publications Verification

    Monoamine Oxidase Apoptosis Neurological Disease Metabolic Disease Endocrinology
    Iproniazid phosphate is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid phosphate inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid phosphate modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid phosphate can be used in the research of depression, Parkinson's disease, and hepatotoxicity .
    Iproniazid phosphate
  • HY-110019

    Lu 19-005

    Serotonin Transporter Dopamine Transporter Neurological Disease
    Indatraline hydrochloride (Lu 19-005) is a non-selective monoamine transporter inhibitor that blocks the reuptake of neurotransmitters (dopamine, serotonin, and norepinephrine). Indatraline hydrochloride can be used for the research of antidepressive. Indatraline hydrochloride induces autophagy while simultaneously inhibiting cell proliferation. Indatraline hydrochloride may also serve to direct the development of new agents for autophagy-related diseases such as atherosclerosis or restenosis .
    Indatraline hydrochloride
  • HY-B2132R
    Tryptamine (Standard)
    1 Publications Verification

    3-(2-Aminoethyl)indole~2-(3-Indolyl)ethylamine (Standard)

    Endogenous Metabolite Others
    Tryptamine (Standard) is the analytical standard of Tryptamine. This product is intended for research and analytical applications. Tryptamine is a monoamine alkaloid, similar to other trace amines, is believed to play a role as a neuromodulator or neurotransmitter.
    Tryptamine (Standard)
  • HY-103465

    Monoamine Transporter Others
    FFN511 is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 inhibits serotonin binding to VMA T2-containing membranes with an IC50 of 1 µM. FFN511 directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .
    FFN511
  • HY-B0528AR

    (±)-p-Octopamine hydrochloride (Standard)

    Reference Standards Adrenergic Receptor Endogenous Metabolite Neurological Disease Endocrinology
    Octopamine (hydrochloride) (Standard) is the analytical standard of Octopamine (hydrochloride). This product is intended for research and analytical applications. Octopamine ((±)-p-Octopamine) hydrochloride, a biogenic monoamine structurally related to noradrenaline, acts as a neurohormone, a neuromodulator and a neurotransmitter in invertebrates. Octopamine hydrochloride can stimulate alpha2-adrenoceptors (ARs) in Chinese hamster ovary cells transfected with human alpha2-ARs. Octopamine hydrochloride increased glycogenolysis, glycolysis, oxygen uptake, gluconeogenesis and the portal perfusion pressure .
    Octopamine hydrochloride (Standard)
  • HY-B0528

    Adrenergic Receptor Endogenous Metabolite Neurological Disease Endocrinology
    Octopamine is a biogenic monoamine structurally related to noradrenaline, acts as a neurohormone, a neuromodulator and a neurotransmitter in invertebrates. Octopamine can stimulate alpha2-adrenoceptors (ARs) in Chinese hamster ovary cells transfected with human alpha2-ARs. Octopamine increased glycogenolysis, glycolysis, oxygen uptake, gluconeogenesis and the portal perfusion pressure .
    Octopamine
  • HY-158555

    Monoamine Transporter Neurological Disease
    4-Ethyl-N,N-Dmc hydrochloride is an analog of Methedrone. Methedrone acts as a non-selective substrate for monoamine transporters, facilitating a neurotransmitter release .
    4-Ethyl-N,N-Dmc hydrochloride
  • HY-14472R

    NS-2330 (Standard)

    Dopamine Transporter Serotonin Transporter Reference Standards Metabolic Disease
    Tesofensine (Standard) is the analytical standard of Tesofensine. This product is intended for research and analytical applications. Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine (DA; IC50=6.5 nM), norepinephrine (NE;IC50=1.7 nM), and serotonin (5-HT;IC50=11 nM), and with potentials as an anti-obesity agent . Tesofensine is a CNS acting anti-obesity agent .
    Tesofensine (Standard)
  • HY-B1473R

    5-Hydroxytryptamine hydrochloride (Standard); 5-HT hydrochloride (Standard)

    5-HT Receptor Reference Standards COMT Endogenous Metabolite Neurological Disease
    Serotonin (5-Hydroxytryptamine) (Standard) hydrochloride is the analytical standard of Serotonin hydrochloride (HY-B1473). This product is intended for research and analytical applications. Serotonin (5-Hydroxytryptamine) hydrochloride is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin hydrochloride is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM.
    Serotonin hydrochloride (Standard)
  • HY-B1473S2

    5-Hydroxytryptamine-13C,D4; 5-HT-13C,D4

    Isotope-Labeled Compounds 5-HT Receptor COMT Endogenous Metabolite Neurological Disease
    Serotonin- 13C,D4 (5-Hydroxytryptamine-13C,D4) is a 13C- and deuterated labeled Serotonin (HY-B1473A). Serotonin is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM .
    Serotonin-13C,D4
  • HY-B1018AS

    Isotope-Labeled Compounds Monoamine Oxidase GABA Receptor Histone Demethylase Cardiovascular Disease Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
    Phenelzine-d5 sulfate is the deuterium labeled Phenelzine sulfate (HY-B1018A). Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer .
    Phenelzine-d5 sulfate
  • HY-174833

    Monoamine Oxidase Neurological Disease
    MAO-A-IN-2 (Compound 4l) is a selective monoamine oxidase A (MAO-A) inhibitor with an IC50 value of 0.4 μM. MAO-A-IN-2 reduces the degradation of monoamine neurotransmitters (e.g., serotonin, norepinephrine). MAO-A-IN-2 is promising for research of neurological diseases related to monoamine neurotransmitter imbalance such as depression and anxiety disorders .
    MAO-A-IN-2
  • HY-18332B

    Dopamine Transporter Adrenergic Receptor 5-HT Receptor Neurological Disease
    DOV-102,677 is an orally sctive triple monoamine neurotransmitter reuptake inhibitor that simultaneously inhibits the dopamine (DAT) (IC50 = 129 nM; Ki = 222 nM), norepinephrine (NET) (IC50 = 103 nM; Ki = 1030 nM), and serotonin (SERT) (IC50 = 133 nM; Ki = 740 nM) transporters. DOV-102,677 demonstrated significant antidepressant-like activity and sensory-motor gating regulatory effects in mouse experiments. DOV-102,677 can be used for research on depression .
    DOV-102,677
  • HY-B2132S

    Isotope-Labeled Compounds Neurological Disease
    Tryptamine-d2 (hydrochloride) is a deuterium labeled Tryptamine hydrochloride. Tryptamine hydrochloride is a monoamine alkaloid, similar to other trace amines, is believed to play a role as a neuromodulator or neurotransmitter .
    Tryptamine-d2 hydrochloride
  • HY-136800

    Thyroid Hormone Receptor Endocrinology
    Posatirelin, a TRH analog, increases monoamine metabolites in the cerebral cortex, nucleus accumbens, and striatum, and possibly exerts CNS activating effects through a modification of several neurotransmitter systems .
    Posatirelin
  • HY-169611

    5-Hydroxytryptamine maleate; 5-HT maleate

    5-HT Receptor COMT Neurological Disease
    Serotonin hydrogen maleate is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin hydrogen maleate is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM .
    Serotonin maleate
  • HY-129488

    R-(-)-BPAP hydrochloride

    Bcl-2 Family Neurological Disease
    FPFS-1169 (hydrochloride) is a proto-oncogene protein c-bcl-2 stimulant. FPFS-1169 (hydrochloride) can increase the impulse-evoked release of monoamine neurotransmitters. FPFS-1169 (hydrochloride) can be studied in research on Parkinson’s disease .
    FPFS-1169 hydrochloride
  • HY-16731

    EVT 302; RG1577; RO4602522

    Monoamine Oxidase Reactive Oxygen Species (ROS) Neurological Disease
    Sembragiline (EVT 302) is a potent, selective and reversible monoamine oxidase B (MAO-B) inhibitor. Sembragiline reduces the metabolism of dopamine and other amine neurotransmitters by inhibiting the activity of the MAO-B enzyme, thereby potentially increasing the concentration of these neurotransmitters in the brain. Inhibition of the MAO-B enzyme also reduces the formation of toxic reactive oxygen species (ROS) that play a role in the pathological process of AD. Sembragiline has good oral activity and blood-brain barrier permeability. Sembragiline can be used in studies of AD, especially in patients with AD who show increased MAO-B activity .
    Sembragiline
  • HY-116062

    Monoamine Transporter Dopamine Transporter Adrenergic Receptor Others
    JNJ-7925476 (hydrochloride) is a triple monoamine uptake inhibitor with the ability to regulate neurotransmitter levels and antidepressant activity. JNJ-7925476 (hydrochloride) can be rapidly absorbed into the plasma in rats, with a higher concentration in the brain than in plasma. It can induce an increase in the levels of extracellular serotonin, dopamine, and norepinephrine in the rat cerebral cortex, and exhibits antidepressant activity in the mouse tail suspension test.
    JNJ-7925476 hydrochloride
  • HY-141554A

    (2S,3S,11bR)-DHTBZ

    Monoamine Transporter Neurological Disease
    (2S,3S,11bR)-Dihydrotetrabenazine ((2S,3S,11bR)-DHTBZ) is a highly selective inhibitor of vesicular monoamine transporter 2 (VMAT2) with a Ki value of 593 nM. (2S,3S,11bR)-Dihydrotetrabenazine inhibits vesicular transport of monoamine neurotransmitters like dopamine and serotonin, reducing their synaptic release. (2S,3S,11bR)-Dihydrotetrabenazine is promising for research of Huntington's chorea and other hyperkinetic disorders .
    (2S,3S,11bR)-Dihydrotetrabenazine
  • HY-103465B

    Monoamine Transporter Others
    FFN511 (hydrochloride) is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 (hydrochloride) inhibits serotonin binding to VMA T2-containing membranes with an IC50 of 1 µM. FFN511 (hydrochloride) directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .
    FFN511 hydrochloride
  • HY-B0528AS

    (±)-p-Octopamine-d4 hydrochloride

    Adrenergic Receptor Endogenous Metabolite Neurological Disease Endocrinology
    Octopamine-d4 (hydrochloride) is the deuterium labeled Octopamine hydrochloride. Octopamine ((±)-p-Octopamine) hydrochloride, a biogenic monoamine structurally related to noradrenaline, acts as a neurohormone, a neuromodulator and a neurotransmitter in invertebrates. Octopamine hydrochloride can stimulate alpha2-adrenoceptors (ARs) in Chinese hamster ovary cells transfected with human alpha2-ARs. Octopamine hydrochloride increased glycogenolysis, glycolysis, oxygen uptake, gluconeogenesis and the portal perfusion pressure .
    Octopamine-d4 hydrochloride
  • HY-117542

    Histone Methyltransferase Neurological Disease
    D595 is a phenylethylamine calcium channel blocker with potent negative inotropic activity. D595 has shown significant efficacy in its corresponding pharmacological studies, especially in inhibiting the uptake of monoamine neurotransmitters. D595 has high affinity in binding to the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET). Structural adjustments of D595, especially changes in the hydroxyl stereochemistry, significantly affect its interaction with the transporters, showing a specific preference for stereoisomers .
    D595
  • HY-B0886AR

    Reference Standards Monoamine Oxidase Apoptosis Neurological Disease Metabolic Disease Endocrinology
    Iproniazid (Standard) is the analytical standard of Iproniazid (HY-B0886A). This product is intended for research and analytical applications. Iproniazid is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid can be used in the research of depression, Parkinson's disease, and hepatotoxicity .
    Iproniazid (Standard)
  • HY-122271

    Endogenous Metabolite Neurological Disease
    Safrazine Hydrochloride is a monoamine oxidase inhibitor with irreversible activity. It is mainly used to inhibit depression and other mood disorders. As a compound, its mechanism is to increase the level of monoamine neurotransmitters in the body by blocking the activity of monoamine oxidase, thereby improving mood and psychological state .
    Safrazine hydrochloride
  • HY-173336

    Monoamine Oxidase Neurological Disease
    MAO-B-IN-42 (Compound 4f) is a selective and reversible inhibitor of monoamine oxidase-B (MAO-B) with an IC50 value of 0.184 μM. MAO-B-IN-42 helps maintain the levels of neurotransmitters by blocking the oxidative deamination of monoamines catalyzed by MAO-B. MAO-B-IN-42 is promising for research of Parkinson's disease .
    MAO-B-IN-42
  • HY-W680886

    Monoamine Transporter Serotonin Transporter Dopamine Transporter 5-HT Receptor Neurological Disease
    6-APDB is a class of monoamine neurotransmitter releaser and Monoamine Transporter modulator that exerts selective effects on human monoamine transporters and acts as a partial agonist at 5-HT2 family receptors. For NET, 6-APDB has an IC50 of 0.56 μM and a Ki of 18 μM; for SERT, it has an IC50 of 2.3 μM and a Ki of 23 μM; for DAT, it has an IC50 of 33 μM and a Ki of >30 μM, and affinity for rat and mouse TAAR1, with Ki values of 1.0 μM and 0.21 μM, respectively. 6-APDB inhibits norepinephrine and 5-HT reuptake, mediates the release of three types of monoamine neurotransmitters, shows a dose-dependent biphasic locomotor effect in mice, and fully substitutes the discriminative stimulus effect of MDMA. 6-APDB shows no significant cytotoxicity at high concentrations, and possesses empathogenic psychoactivity, potential hallucinogenic effects, and behavioral effects associated with intermittent abuse .
    6-APDB
  • HY-174834

    Monoamine Oxidase Neurological Disease
    MAO-B-IN-44 (Compound 4n) is a selective monoamine oxidase B (MAO-B) inhibitor targetin with an IC50 value of 1.01 μM, showing weak inhibition on MAO-A (IC50=14.4 μM). MAO-B-IN-44 reduces degradation of neurotransmitters like dopamine. MAO-B-IN-44 is promising for research of neurodegenerative diseases related to MAO-B abnormalities such as Parkinson’s disease .
    MAO-B-IN-44
  • HY-103465R

    Reference Standards Monoamine Transporter Others
    FFN511 (Standard) is the analytical standard of FFN511 (HY-103465). This product is intended for research and analytical applications. FFN511 is a potent fluorescent false neurotransmitters (FFNs) that targets neuronal vesicular monoamine transporter 2 (VMA T2). FFN511 inhibits serotonin binding to VMA T2-containing membranes with an IC50 of 1 μM. FFN511 directly images the dynamics of release during exocytosis, can be used to label dopamine terminals in live cortical-striatalacute slices .
    FFN511 (Standard)
  • HY-B0886R

    Reference Standards Monoamine Oxidase Apoptosis Neurological Disease Metabolic Disease Endocrinology
    Iproniazid (phosphate) (Standard) is the analytical standard of Iproniazid phosphate (HY-B0886). This product is intended for research and analytical applications. Iproniazid phosphate is an orally active, irreversible, non-selective monoamine oxidase (MAO) inhibitor. Iproniazid phosphate inhibits MAO activity and enhances Rotenone (HY-B1756)-induced Apoptosis. Iproniazid phosphate modulates neurotransmitter levels, affects neuronal function, induces hepatic necrosis, and interferes with the endocrine system. Iproniazid phosphate can be used in the research of depression, Parkinson's disease, and hepatotoxicity .
    Iproniazid phosphate (Standard)

Consulta en línea

Your information is safe with us. * Required Fields.

Saludo

 

Country or Region *

Nombre del solicitante *

 

Nombre de la Organizaciòn *

Department *

     

Direcciòn del E-mail *

 

Nombre del producto *

Cat. No.

 

Requested quantity *

Número de teléfono *

     

Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: